Condition: Alzheimer Disease · Mild Cognitive Impairment (MCI) · Subjective Cognitive Decline (SCD) · Sponsor: Massachusetts General Hospital
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
This description comes directly from the study's public registry record.
Gene Bowman, N.D., M.P.H. · 857-282-5197 · glbowman@mgh.harvard.edu
Brianna Wang · 857-282-1520 · bwang34@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07236190